ClinicalTrials.gg
CompletedNCT04997902Updated Sep 8, 2026

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

A Phase 1/2 interventional study of Tipifarnib and Alpelisib in HNSCC, sponsored by Kura Oncology, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Kura Oncology, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
457th of 993
45 · median 41
Started
2021
with 75 others
Phase 1/2
157 of 1,099
42 open now
Registered
769th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 457th largest by enrollment of the 993 interventional ones that give a count, is one of 76 that started in 2021, is one of 157 in phase 1/2, and was the 769th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.

03

Conditions studied

  • HNSCC

Keywords

  • HRAS
  • PIK3CA
  • PI3K
  • Tipifarnib
  • Alpelisib
  • R/M HNSCC (Recurrent/metastatic Head and Neck Squamous Cell Carcinoma)
  • Head and Neck Cancer
  • SCCHN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age.
  2. confirmed head and neck cancer of squamous histology not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
  3. Documented treatment failure from at least 1 prior systemic therapy in the R/M setting, unless determined not appropriate.
  4. by (RECIST) v1.1.
  5. Has a tumor that is dependent upon HRAS and/or PIK3CA.
  6. (ECOG) performance status of 0-1.
  7. Acceptable liver, renal, endocrine, and hematologic function.
  8. Must be able to swallow alpelisib whole tablet or oral suspension containing crushed tablets. Feeding tube may not be used for alpelisib administration.
  9. Other protocol defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  1. confirmed salivary gland, thyroid, (primary) cutaneous squamous or nonsquamous histologies (eg, mucosal melanoma).
  2. Ongoing treatment with certain anticancer agents.
  3. Prior treatment (at least 1 full treatment cycle) with an FTI or PI3K, mTOR, or AKT inhibitor.
  4. Received treatment for unstable angina, myocardial infarction, and/or cerebro-vascular attack within the prior 6 months.
  5. Non-tolerable Grade 2, or ≥ Grade 3 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1.
  6. Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.
  7. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
  8. Participant with an established diagnosis of diabetes mellitus Type 1 or not controlled Type 2.
  9. Participant has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the trial drugs based on Investigator discretion.
  10. Participant has currently documented pneumonitis/interstitial lung disease.
  11. Participant has a history of severe cutaneous reaction, such as Stevens-Johnson Syndrome (SJS), Erythema Multiforme (EM), Toxic Epidermal Necrolysis (TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
  12. Other protocol defined exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    PIK3CA-dependent (Cohort 1)

    Adult participants with R/M HNSCC whose tumors harbor PI3KCA (activating) mutations and/or amplifications

    Drug: Tipifarnib · Drug: Alpelisib

  • Experimental
    HRAS-dependent (Cohort 2)

    Adult participants with R/M HNSCC whose tumors have increased HRAS dependency, defined as HRAS overexpression

    Drug: Tipifarnib · Drug: Alpelisib

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Rate of DLTs evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. A Treatment-Emergent Adverse Event (TEAE) is an AE occurring on or after Cycle 1 Day 1 and within 30 days of the last dose of tipifarnib or alpelisib, whichever is later. Patients with multiple events are counted only once at the highest CTCAE grade.

    Time frame: First 28 days (1 cycle) of combination therapy

  2. Descriptive statistics of Adverse Events (AEs)

    Descriptive statistics of Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs; AE severity will be assessed per the NCI CTCAE v 5.0. AEs are coded using the MedDRA dictionary version 28.0. A TEAE is an AE occurring on or after Cycle 1 Day 1 and within 30 days of the last dose of tipifarnib or alpelisib, whichever is later. At each level of summation (system organ class, preferred term), a patient reporting more than one adverse event is counted only once.

    Time frame: From Cycle 1 Day 1 until 30 days after last trial intervention dose or 30 days after trial completion, whichever comes first, assessed up to 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Defined as the proportion of participants with best overall response as a confirmed complete response (CR) or confirmed partial response (PR) by RECIST v1.1. Clopper-Pearson 95% confidence intervals are calculated based on binomial distribution.

    Time frame: From Cycle 1 Day 1 until first documentation of disease progression, the start of new anti-cancer therapy, or death, whichever occurs first, assessed up to 2 years

  2. Median duration of response

    Defined for participants with confirmed objective response as the time from the first documentation of response to the first documentation of disease progression by RECIST v1.1 or to death due to any cause before new anti-cancer treatment, whichever occurs first. Median is calculated using Kaplan-Meier method. Confidence interval for median is calculated using the Brookmeyer-Crowley method. Minimum and maximum are actual values rather than estimates.

    Time frame: From first documentation of response to first documentation of disease progression, the start of new anti-cancer therapy, or death, whichever occurs first, assessed up to 2 years

  3. Disease control rate (DCR)

    Disease control rate (CR + PR + SD)

    Time frame: From Cycle 1 Day 1 until first documentation of disease progression, the start of new anti-cancer therapy, or death, whichever occurs first, assessed up to 2 years

  4. Median duration of Disease Control

    Defined for participants with confirmed objective response as the time in months from the first documentation of response to the first documentation of disease progression by RECIST v1.1 or to death due to any cause before new anti-cancer treatment, whichever occurs first, in patients with confirmed CR/PR

    Time frame: From first documentation of response until first documentation of disease progression, the start of new anti-cancer therapy, or death, whichever occurs first, assessed up to 2 years

  5. Rate of Stable Disease

    Time frame: From Cycle 1 Day 1 until first documentation of disease progression, the start of new anti-cancer therapy, or death, whichever occurs first, assessed up to 2 years

  6. Median duration of Stable Disease (SD)

    Defined as durable SD (\>= 12 weeks) by RECIST v1.1

    Time frame: From first documentation of response until first documentation of disease progression, the start of new anti-cancer therapy, or death, whichever occurs first, assessed up to 2 years

  7. Cmax of tipifarnib and alpelisib when administered in combination

    Maximum observed concentration following single dose and multiple dose administration

    Time frame: Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.

  8. Tmax of tipifarnib and alpelisib when administered in combination

    Time to reach maximum observed concentration following single dose and multiple dose administration

    Time frame: Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.

  9. AUC(0-last) of tipifarnib and alpelisib when administered in combination

    Area under the concentration-time curve from time zero to time of last quantifiable concentration following single dose and multiple dose administration

    Time frame: Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.

  10. AUC(tau) of tipifarnib and alpelisib when administered in combination

    Area under the concentration-time curve during a dosage interval following single dose and multiple dose administration

    Time frame: Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.

  11. AUC(0-infinity) of tipifarnib and alpelisib when administered in combination

    Area under the concentration-time curve from time zero to infinity following single dose administration

    Time frame: Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.

  12. CL/F of tipifarnib and alpelisib when administered in combination

    Apparent total clearance of the drug following single dose and multiple dose administration

    Time frame: Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.

  13. Vd/F of tipifarnib and alpelisib when administered in combination

    Apparent volume of distribution following single dose and multiple dose administration

    Time frame: Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.

  14. Half-life of tipifarnib and alpelisib when administered in combination

    Time required for the amount of drug in the body to decrease by half following single dose and multiple dose administration

    Time frame: Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.

  15. Accumulation ratio of tipifarnib and alpelisib when administered in combination

    Defined as the ratio of drug exposure at steady state to exposure following a single dose. For tipifarnib, the accumulation ratio was calculated as the ratio of area under the plasma concentration-time curve over the dosing interval (AUCτ) on Cycle 2 Day 1 (C2D1) to AUC from time zero to 12 hours (AUC₀-12) on Cycle 1 Day 1 (C1D1). For alpelisib, the accumulation ratio was calculated as the ratio of AUCτ on C2D1 to AUC from time zero to 24 hours (AUC₀-24) on C1D1.

    Time frame: Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.

  16. Progression-free survival (PFS)

    Defined as the time in months from C1D1 to the first documentation of disease progression or death due to any cause before new anti-cancer treatment. Median is calculated using Kaplan-Meier method. Confidence interval for median is calculated using the Brookmeyer-Crowley method. Minimum and maximum are actual values rather than estimates.

    Time frame: From Cycle 1 Day 1 until first documentation of disease progression, the start of new anti-cancer therapy, or death, whichever occurs first, assessed up to 3 years

  17. Proportion of participants with PFS at 6 months

    Proportion of participants alive and without disease progression at 6 months and before new anti-cancer treatment. Survival probability and confidence interval are calculated based on Kaplan-Meier product-limit method and Greenwood's formula.

    Time frame: From Cycle 1 Day 1 until first documentation of disease progression, the start of new anti-cancer therapy, or death, whichever occurs first, assessed up to 6 months

  18. Overall Survival (OS)

    OS is the time in months from C1D1 to the date of death due to any cause. For patients with no events, OS will be censored at the last known to be alive date. Median is calculated using Kaplan-Meier method. Confidence interval for median is calculated using the Brookmeyer-Crowley method. Minimum and maximum are actual values rather than estimates.

    Time frame: From Cycle 1 Day 1 until 3 years of treatment or death from any cause, whichever comes first

  19. Proportion of patients with OS at 12 months

    Proportion of participants alive at 12 months. For patients with no events, OS will be censored at the last known to be alive date. Survival probability and confidence interval are calculated based on Kaplan-Meier product-limit method and Greenwood's formula.

    Time frame: From Cycle 1 Day 1 until 12 months of treatment or death from any cause, whichever comes first

07

Study locations

11 sites
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Lake Nona DDU (Florida Cancer Specialists)
    Orlando, Florida 32827, United States
  • University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center)
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center)
    Baltimore, Maryland 21231, United States
  • Dana-Farber Cancer Institute (Head and Neck Cancer Treatment Center)
    Boston, Massachusetts 02215, United States
  • Washington University, School of Medicine
    St Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • UT Southwestern Medical Center (Harold C. Simmons Comprehensive Cancer Center)
    Dallas, Texas 75390, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Aug 2025, 44 months.

Of 93 industry-sponsored phase 1/2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 44 months is below that.

Counting every sponsor, half of 138 studies reached it within 61 months; a quarter within 47 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2021
First posted
Aug 10, 2021
StartActual
Dec 7, 2021
Primary completionActual
Aug 29, 2025
CompletionActual
Aug 29, 2025
Results delay requested
Aug 25, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04997902
Lead sponsor
Kura Oncology, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
Dec 7, 2021
Primary completion
Aug 29, 2025
Completion
Aug 29, 2025
Last update
Sep 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipifarnib · Alpelisib

Start the discussion